Arterra Bioscience SpaMIL: ARBS

ARBS: H1 2025 saw 35.5% revenue growth, 143% EBITDA increase, and robust net profit margin

· Issued by Arterra Bioscience Spa

Production value grew 35.5% to €3.1M in H1 2025, with EBITDA up 143% and net profit at €1.1M. Strong cash position, improved margins, and ongoing R&D support a positive outlook, with sales momentum continuing into H2.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Arterra Bioscience Spa

All Arterra Bioscience Spa news releases